Lilly says Foundayo 17.2 mg beat Novo Ozempic 25 mg in type 2 diabetes analysis
Lilly cited an indirect comparison of late-stage studies showing Foundayo 17.2 mg delivered 1.5%-2.4% more weight loss and 0.3%-0.6% larger A1C reductions than oral semaglutide 25 mg (Ozempic/Rybelsus) in adults with type 2 diabetes.